Nabi Biopharmaceuticals (NABI) Reports Q1 Loss of $0.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mailGet Alerts NABI Hot Sheet
Join SI Premium – FREE
Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q1 EPS of ($0.03), versus $0.05 reported last year. Revenue for the quarter came in at $600 thousand, versus $9.17 million reported last year.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Parabolic reports preliminary Q3 2026 revenue of $4.7 million
- FDA approves Pfizer's Tukysa as front-line maintenance for HER2+ breast cancer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
